Group 1: Product Sales and Market Expansion - The company is focusing on extensive training for doctors and patients to enhance the sales of Conbercept eye injection, aiming to explore untapped markets [4] - The overseas commercialization of Conbercept is a significant priority, with ongoing global multi-center clinical trials expected to reveal its market value [4] - The global multi-center clinical trial for Conbercept involves over 300 research centers across more than 30 countries, with plans to enroll over 2,000 participants, and the enrollment is already over half complete [4] Group 2: Competitive Advantages and Regulatory Preparedness - Conbercept has been recognized by the WHO with the international non-proprietary name "Conbercept," and it has received FDA approval to skip Phase I and II trials, directly proceeding to Phase III, indicating its technical and safety recognition [5] - The company is preparing for the upcoming national medical insurance negotiations by showcasing the advantages of Conbercept and its contributions [6] Group 3: Research and Development Capabilities - The company has established several innovative platforms, including a national recognized technical center and a postdoctoral research station, to enhance its drug development capabilities [6] - Focus areas for R&D include large molecule protein drug technology, standardized quality control for traditional Chinese medicine, green synthesis of chemical raw materials, and new formulations for solid oral drugs [6] - The company has structured its R&D into three main segments: new drug research, product technology center, and medical research center, integrating domestic and international resources for a comprehensive innovation team [6]

Group 1: Company Overview - Chengdu Kanghong Pharmaceutical Group Co., Ltd. focuses on clinical needs and core therapeutic areas, particularly in ophthalmology and neurology [2][4] - The company has developed a series of products, including traditional Chinese medicine and chemical drugs, with an emphasis on filling market gaps and competing internationally [4][5] Group 2: Product Development - The first product, Songling Xuemai Kang capsules, targets hyperlipidemia and hypertension, marking a significant entry into traditional Chinese medicine [4] - Kanghong's Conbercept (Kangbaisipu) has received approval for three indications: wet age-related macular degeneration (wAMD), myopic choroidal neovascularization (pmCNV), and diabetic macular edema (DME) [5][8] - The company is advancing multiple clinical trials, including a global Phase III trial for Conbercept, with over half of the participants enrolled [6][8] Group 3: Financial Strategy - Kanghong plans to issue convertible bonds not exceeding CNY 1.63 billion to fund the industrialization of KH series biological new drugs and international clinical trials for Conbercept [6][8] Group 4: Research and Development - The company has established a robust R&D framework, including a national recognized technical center and a postdoctoral research station, focusing on innovative drug development [9] - Kanghong has implemented an equity incentive plan covering over 400 employees to enhance motivation and performance [9] Group 5: Market Positioning - The company is preparing for the next round of national medical insurance negotiations, aiming to leverage product advantages and contributions to secure favorable outcomes [8]

Group 1: Company Overview - Chengdu Kanghong Pharmaceutical Group Co., Ltd. is focused on developing innovative drugs and has a strong emphasis on self-sustaining capabilities in drug development [2][4]. - The company aims to enhance the pharmaceutical level in China through original technology capabilities [4]. Group 2: Research and Development Strategy - The company is strategically positioning its biopharmaceutical pipeline by focusing on clinically validated targets to improve success rates and reduce risks [5]. - Kanghong is also exploring new mechanisms and molecules, while balancing the development of biosimilars to maintain competitiveness [5][6]. Group 3: Product Development Focus - Kanghong is actively working on products for the treatment of myopia and has ongoing research in this area [5]. - The company is investing in gene therapy, with plans to develop a platform that focuses on major diseases with significant medical needs [6]. Group 4: Team and Innovation Management - The company emphasizes a balanced approach to innovation, assessing both high-risk and low-risk projects in its R&D pipeline [6]. - Kanghong aims to build a capable team that can realize the company's vision, leveraging the experience of its leadership to train team members [6].

Group 1: Company Overview - Chengdu Kanghong Pharmaceutical Group Co., Ltd. is focused on innovative drug research and development, particularly in the central nervous system field [2][4]. - The company has a commitment to long-term goals and sustainable operations, with significant investments in R&D [4]. Group 2: R&D Strategy - The company aims to establish an efficient R&D team and continuously seek specialized talent in relevant fields [5]. - Kanghong's research areas include ophthalmology, central nervous system disorders, and oncology, with a focus on diseases lacking satisfactory treatment options, including rare diseases [6]. Group 3: Project Management and Success Rates - The company employs a balanced project strategy, including First in Class, Best in Class, and Fast Follower projects, to enhance the success rate of R&D [6]. - Kanghong emphasizes the importance of translational medicine, especially for multi-target drugs, to improve clinical research speed and success rates [7]. Group 4: Team and Collaboration - The company has established a collaborative environment with domestic and international research institutions to explore new targets and innovative treatment pathways [6]. - Kanghong's project management is structured to facilitate efficient progress, with independent project management teams formed at the candidate compound stage [7].

Group 1: Company Strategy and Market Position - The company is adapting to changes in the pharmaceutical industry due to new policies and will implement measures accordingly [4] - The promotion of the drug Conbercept (康柏西普) involves extensive training for doctors and patients to increase sales and expand into untapped markets [4] - The overseas commercialization of Conbercept is a key focus, with ongoing global multi-center clinical trials to enhance market value [5] Group 2: Clinical Trials and Product Development - The global multi-center clinical trial for Conbercept involves over 200 research centers across more than 30 countries, with plans to enroll over 2,000 participants [5] - The company is preparing for the upcoming national medical insurance negotiations, aiming to showcase the advantages of Conbercept to achieve favorable outcomes [5] - The company is actively seeking innovative projects globally that align with its strategic goals [6] Group 3: Product Pipeline and Innovations - The company is enhancing its product pipeline based on clinical needs, focusing on core therapeutic areas such as ophthalmology and neurology [6] - Conbercept has received approval for three indications: wet age-related macular degeneration (wAMD), myopic choroidal neovascularization (pmCNV), and diabetic macular edema (DME), with ongoing phase III clinical trials [7] - The company is developing KH906 eye drops for treating trauma and chemical burns, which has received clinical trial approval [7]

证券代码：002773 证券简称：康弘药业 成都康弘药业集团股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |----------------|-------------------------------------------------------|-------|-------|-------| | | □ 特定对象调研 □分析师会议 | | | | | 投资者关系活动 | □媒体采访 √业绩说明会 | | | | | 类别 | □ 新闻发布会 □路演活动 | | | | | | □现场参观 | | | | | | □ 其他 | | | | | 参与单位名称及 | 投资者 | | | | | | | | | | | 人员姓名 | | | | | | 时间 | 2019 年 5 月 9 日 | | | | | 地点 | " 全 景 · 为： http://rs.p5w.net/c/002773.shtml | （ | | 地 址 | | 上市公司接待人 | 董事长：柯尊洪先生 | | | | | 员姓名 | 董事、总裁：郝晓锋先生 | | | | | | ...

Group 1: Financial Performance and Distribution - The proposal for the profit distribution and capital reserve increase was approved at the board meeting on April 26, 2019, and the shareholders' meeting on May 20, 2019 [4] - The specific date for the rights registration is being coordinated with relevant departments, and further announcements will be made [4] - The company experienced a significant increase in inventory in 2018, attributed to operational needs [5] Group 2: Market and Sales Insights - The sales of traditional Chinese medicine saw a decline in 2018, and the company is working towards recovery [5][11] - The company is actively expanding its market presence and is progressing according to its plans [8] - The revenue share from traditional Chinese medicine has decreased significantly compared to 2017 due to changes in marketing strategies and related policies [10][11] Group 3: Clinical Trials and International Operations - The company has invested $228 million over eight years for Phase III clinical trials in the U.S. and Europe, with significant progress reported [10][11] - The international multi-center Phase III clinical research has received approvals in 25 countries or regions, with over 200 research centers involved [10][11] Group 4: Corporate Governance and Shareholding - The major shareholder's stake is approximately 70%, while another fund holds about 10% of the shares, facing liquidation due to fund expiration [11][12] - The company is committed to optimizing its corporate governance structure in accordance with legal requirements [12]

证券代码：002773 证券简称：康弘药业 成都康弘药业集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------------|------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | √ 其他 上市公司投资者交流会 | | | 参与单位名称及 | | 证券公司、基金公司、资产管理公司等 | | 人员姓名 | | | | 时间 | 2018 年 6 月 1 日 | 10:30-12:00 | | 地点 | 成都市金牛区蜀西路 | 36 号公司一楼会议室。 | | 上市公司接待人 | 董事长：柯尊洪先生 | | | 员姓名 | 董事、总裁：郝晓锋先生 | | | | 董事、常务副总裁：柯潇先生 | | | | | 副总裁、财务总监、董秘：钟建军先生 | 编号：2018-04 1 / 14 ...

证券代码：002773 证券简称：康弘药业 成都康弘药业集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | √ 其他 上市公司投资者交流会 | | | 参与单位名称及 | | 证券公司、资产管理公司等（名单附后，按参加活动人员所 | | 人员姓名 | 属机构名称拼音首字母排序） | | | 时间 | 2018 年 5 月 15 | 日 10:30-11:30 | | 地点 | 成都市金牛区蜀西路 | 36 号公司四楼会议室。 | | 上市公司接待人 | | | | 员姓名 | | 副总裁、财务总监、董秘：钟建军先生 | | 投资者关系活动 | | 本次投资者交流会对公司基本情 ...

证券代码：002773 证券简称：康弘药业 成都康弘药业集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------------|--------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | √ 其他 上市公司投资者交流会 | | | 参与单位名称及 | | 证券公司、基金公司、资产管理公司等 | | 人员姓名 | | | | 时间 | 2018 年 5 月 21 | 日 14:00-16:00 | | 地点 | 成都市金牛区蜀西路 | 36 号公司四楼会议室。 | | 上市公司接待人 | | | | 员姓名 | | 副总裁、财务总监、董秘：钟建军先生 | | 投资者关系活动 | | 本次投资者交流会对公司基本情况进行了介绍，并与投 | 编号：2018-03 1 / ...